Bantam Pharmaceutical

Executive Summary

Bantam Pharmaceutical is a private biotechnology company pioneering first-in-class, oral small molecule therapeutics that target mitochondrial dynamics to restore apoptosis in cancer cells. Founded in 2018 and based in Cambridge, MA, the company focuses on difficult-to-treat hematological and solid tumors. Its lead candidate, BTM-3566, is an orally available compound that has demonstrated broad preclinical anti-cancer activity, positioning it as a potential breakthrough in oncology. By uniquely altering mitochondrial function, Bantam aims to overcome resistance mechanisms common in current therapies, offering a novel approach to cancer treatment. Currently in the pre-clinical stage, Bantam is advancing BTM-3566 toward the clinic, with IND-enabling studies underway. While financial details and valuation remain undisclosed, the company's innovative mechanism and early preclinical success suggest significant upside potential. Key upcoming milestones include the completion of IND-enabling toxicology studies, potential regulatory filings, and initial clinical trial initiation. As a private entity, Bantam may also explore strategic partnerships to support development and commercialization. Investors should monitor progress in mitochondrial dynamics modulation as a promising new axis in cancer therapy.

Upcoming Catalysts (preview)

• 2027IND Submission for BTM-356660% success
• H2 2026Preclinical Data Presentation at Major Conference80% success
• TBDStrategic Partnership or Licensing Deal30% success